Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858980 | 0.86 | POLB (0.30) | POLBHCAR2 | |
| SCHEMBL748571 | 0.84 | CHRNB2 (0.34) | POLBHCAR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL15463774 | 0.78 | CYP11B2 (0.36) | POLBHCAR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1356433 | 0.78 | CYP11B1 (0.43) | POLBHCAR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30132809 | 0.78 | CYP11B1 (0.43) | POLBHCAR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL27996891 | 0.77 | DRD2 (0.48) | — | |
| SCHEMBL12832868 | 0.76 | POLB (0.31) | POLBHCAR2CHRNB2CHRNA4 | |
| SCHEMBL16007499 | 0.76 | HCRTR1 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL30324785 | 0.75 | CYP11B1 (0.44) | TSHRHCAR2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30324613 | 0.75 | CYP11B1 (0.44) | TSHRHCAR2CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023036217-A1 | ACRYLAMIDE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-03-16 | — | — | WO | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9242966-B2 | Phthalazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242966-B2 | Phthalazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242966-B2 | Phthalazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2970179-A1 | PHTHALAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970296-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| EP-2430011-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130794-A1 | 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNJ2, KCNA4 | TSHR 275/4885POLB 3412/4885HCAR2 1689/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | TSHR 2407/4885POLB 2259/4885HCAR2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.